Retatrutide: A Comprehensive Guide to the Weight Loss Drug
3상 임상시험에서 최대 24.2%의 체중 감량이라는 유망한 결과를 보여주고 있는 혁신적인 약물, "Retatrutide 체중 감량 약 개요"를 확인해보세요.
Reconstitution Guide: Learn how to safely reconstitute retatrutide — step-by-step instructions, dosage calculations, and safety checks. Read the full guide →
개요
Retatrutide는 GLP-1, GIP 및 글루카곤 수용체를 표적으로 하는 삼중 호르몬 수용체 작용제입니다. 이는 차세대 비만 약물치료를 대표합니다.
Key Information
Mechanism
GLP-1(식욕 억제), GIP(인슐린 감수성 향상), 글루카곤(지방 산화 및 열생성) 수용체에 대한 삼중 작용(트리플 아고니즘).
Benefits
- 최대 24.2% 체중 감량
- 삼중 호르몬 작용제
- 임상 시험 중 최고 효능
Side Effects
- 메스꺼움
- 설사
- 구토
Contraindications
- Not studied in pregnancy
Evidence Summary
2상 시험에서 48주 시점에 24.2%의 체중 감소가 나타났습니다. 3상 TRIUMPH 시험은 진행 중입니다.
Research
2상 임상시험에서 48주 시점에 최대 24.2%의 체중 감소가 나타났으며, 이는 임상시험에서 측정된 어떤 펩타이드보다도 가장 높은 수치입니다.
View ResearchSafety
GLP-1 계열과 유사한 위장관(GI) 부작용. 현재 임상 3상 개발 단계에 있음.
Retatrutide Weight Loss Drug Overview
Retatrutide for weight loss is under study as a triple hormone receptor agonist. It acts on GLP-1, GIP, and glucagon receptors. This new weight loss drug retatrutide is a next-gen obesity drug candidate.
Key Information
- Also known as: LY3437943
- Sequence: triple agonist peptide
- CAS number: 2378660-54-7
- Molecular formula: C221H342N46O48
- Half-life: 6 days
- Use: shot under the skin
- Dose range: 1-12 mg each week
- Price range: $4.0–$35.0/mg
- Storage: keep cold at 2-8C
- Mix: mix with sterile water
- US status: investigational (Phase 3)
- Legal status: not yet FDA-approved
- Phase 3 TRIUMPH trials: ongoing
- Research papers: 1 indexed
Mechanism
Retatrutide acts on three targets.
- GLP-1 may curb appetite.
- GIP may help insulin use.
- Glucagon may help fat burn and heat production.
Benefits
- Up to 24.2% weight loss
- Triple hormone agonist
- Strong trial results
Side Effects
- Nausea
- Diarrhea
- Vomiting
Warnings
- Not studied in pregnancy
Evidence Summary
Phase 2 showed up to 24.2% weight loss at 48 weeks.
Phase 3 TRIUMPH trials are still ongoing.
Research
Phase 2 trials showed up to 24.2% weight loss at 48 weeks. That is the best result yet for a peptide in trials. View the research papers indexed on our research page.
Safety
Side effects were similar to those seen with the GLP-1 class.
Retatrutide medication is still in Phase 3 study.
Legal Status
Still under study. Not yet FDA-approved. In Phase 3 TRIUMPH trials.
Frequently Asked Questions About Retatrutide
What is Retatrutide?
Retatrutide is a research peptide. It is also known as LY3437943. It is a retatrutide triple hormone receptor agonist being studied for weight loss. It is being studied for medical use. It is also sold by research chemical vendors.
How does Retatrutide work?
It acts on GLP-1, GIP, and glucagon receptors. The retatrutide GLP-1 effect may curb appetite. GIP may help insulin use. Glucagon may help fat burn and heat.
Is retatrutide a GLP 3 drug?
No. Search terms like glp retatrutide, retatrutide glp 3, glp3 retatrutide, and retatrutide glp-1 are common. They do not describe a standard drug class. Retatrutide is better described as a triple hormone receptor agonist.
What is the recommended dosage for Retatrutide?
The most studied dose range is 1-12 mg each week. Dose plans vary by study goal. Read published studies first, and start low. Retatrutide should only be used in controlled research settings.
Where can I buy Retatrutide?
PepsReview lists retatrutide weight loss pricing from many vendors. Check the Vendors tab for a price compare table with cost per milligram, purity, COA status, and stock. User reviews from real buyers are on each vendor profile page.
Is Retatrutide legal?
US status: investigational, Phase 3. It is not yet FDA-approved. It is in Phase 3 TRIUMPH trials.
What are the side effects of Retatrutide?
Reported side effects include nausea, diarrhea, and vomiting. Always review safety data and published studies before use.
Key Research Papers on Retatrutide
The following peer-reviewed studies and clinical trials are indexed in our research library for Retatrutide. Each paper links to a short summary with key findings, study design, and publication data.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med, 2023 (450 citations)
Related Weight Loss / Metabolic Peptides
Other peptides in the weight loss / metabolic group may be useful for comparison research:
- Semaglutide — GLP-1 receptor agonist for weight loss and diabetes management
- Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
- Survodutide — Dual GLP-1/glucagon agonist in development
- Liraglutide — First-gen GLP-1 agonist, daily injection
- AOD-9604 — Modified growth hormone fragment for fat burning
Key Research Papers on Retatrutide: A Comprehensive Guide to the Weight Loss Drug
The following peer-reviewed studies and clinical trials are indexed in our research library for Retatrutide: A Comprehensive Guide to the Weight Loss Drug. Each paper links to a detailed summary with key findings, study design, and publication metadata.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med, 2023 (450 citations)
- The power of three: Retatrutide's role in modern obesity and diabetes therapy — Eur J Pharmacol, 2024 (40 citations)
- Retatrutide-A Game Changer in Obesity Pharmacotherapy — Biomolecules, 2025 (20 citations)
Related Weight loss / Metabolic Peptides
Other peptides in the weight loss / metabolic category that may be of interest for comparative research:
Vendor Price Comparison
| Product | Vendor | Size | Price | $/mg | Purity | COA | Stock | Visit |
|---|---|---|---|---|---|---|---|---|
| Retatrutide 20mg | 20.0mg | $71.00 | $3.55 | 99.7% | SideChain Analytics (HPLC-MS/MS) (1d) | In Stock | Visit | |
| GLP-3R 20mg Research Peptide | 20.0mg | $78.00 | $3.90 | 99% | — | In Stock | Visit | |
| Retatrutide 10mg | 10.0mg | $52.00 | $5.20 | 99.7% | SideChain Analytics (HPLC-MS/MS) (1d) | In Stock | Visit | |
| Retatrutide 30mg | 30.0mg | $199.00 | $6.63 | 99%+ | — | In Stock | Visit | |
| Retatrutide 10mg | 10.0mg | $69.00 | $6.90 | 99%+ | — | In Stock | Visit | |
| Retatrutide 20mg | 20.0mg | $179.00 | $8.95 | 99%+ | — | In Stock | Visit | |
| Retatrutide 10mg | 10.0mg | $121.00 | $12.10 | 99%+ | Janoshik (7d) | In Stock | Visit | |
| Retatrutide 10mg | 10.0mg | $139.99 | $14.00 | 99%+ | — | In Stock | Visit |
Write a Review
Login to write a review
You need an account to share your experience with Retatrutide: A Comprehensive Guide to the Weight Loss Drug.
가입Rating Breakdown
Based on 3 리뷰.
리뷰
Started taking Reta in May 2026 and 3 months later I'm down 33 lbs. Taking 6mg but weight loss has gotten slower. Thinking about going up to 8mg. The triple agonist mechanism is unreal.
Reta reversed my type 2 diabetes. A1C normalized within 4 months. Also lost 25 lbs. The heart rate increase is real though - monitoring that closely with my doctor.
Down 28 lbs in 4 months. The weight loss is unmatched but increased heart rate is a real side effect. Also noticed it blunted my dopamine - lost interest in unhealthy habits which was actually positive.
Community Discussions on Retatrutide
Join the conversation in our peptide community forum. Real users share their retatrutide experiences, dosing schedules, results, and tips.
View all Retatrutide forum discussions